Other Recent Articles


Mass Torts Update - Aug 14, 2015 14:23 - 0 Comments

An Update On The Drug Invokana

Johnson & Johnson’s Invokana, approved by the U.S. Food and Drug Administration (FDA) in March 2013, is prescribed to people with Type 2 diabetes. When Invokana was approved, it was the first drug in a new class known as sodium-glucose cotransporter-2 (SGLT2) inhibitors. These drugs help prevent high blood sugar levels by causing the kidneys to remove excess blood sugar through urine. Continue…

More In Mass Torts


Product Liability - Sep 2, 2015 13:13 - 0 Comments

Jeep Grand Cherokees Under NHTSA Probe After Rollaway Reports

The National Highway Transportation Safety Administration has begun investigating nearly half a million Jeep Grand Cherokees after receiving 14 reports from consumers that their parked Jeeps rolled away, with the engine running and with it off. NHTSA has opened a preliminary evaluation into 408,000 model year 2014 and 2015 Jeep Grand Cherokees after the agency was contacted more than a dozen times by drivers complaining that their vehicles rolled away after the gears were shifted into the “park” position. The Jeeps are equipped with a gear selector that, rather than working the way traditional gear selectors do, allows a selection to be made by pressing the shifter paddle forward and backward, NHTSA said. The preliminary evaluation will assess the scope, frequency and safety related consequences of the purported defect.

Source: Law360.com

More In Personal Injury


Drug Manufacturer Fraud Litigation - Sep 4, 2015 12:43 - 0 Comments

Amgen Pays $71 Million In Multistate Drug-Marketing Settlement

Amgen Inc. has agreed to a $71 million settlement with 48 state attorneys general who accused the drugmaker of marketing its anemia drug Aranesp and plaque psoriasis drug Enbrel, both biologic medications, for uses beyond the scope of U.S. Food and Drug Administration (FDA) approval. The drugmaker, based in California, agreed to a consent judgment last month with New York Attorney General Eric Schneiderman and other Attorneys General after they claimed it marketed Aranesp for cancer-related anemia without FDA approval and promoted Enbrel to treat mild plaque psoriasis – an auto-immune problem that causes the flaking and scaling of skin cells – even though the drug is only approved for more serious forms of the condition. Continue…

More In Fraud